Peer-influenced content. Sources you trust. No registration required. This is HCN.

Oncology Learning NetworkFDA Approves Tremelimumab Plus Durvalumab and Platinum-Based Chemotherapy for Metastatic NSCLC

This approval was based on findings from the open-label, randomized, multicenter POSEIDON trial, which compared data from two of the study’s three treatment arms. When compared to patients in the other treatment arm, patients in this group had a significantly improved OS, with a median OS of 14 months as opposed to 11.7 months.